Survodutide produced 12.2% average weight loss with the 3.6 mg dose and 13.0% with the 6.0 mg dose at 76 weeks in the prespecified primary analysis of the phase 3 SYNCHRONIZE-1 trial. Placebo participants lost 5.4% on average. The peer-reviewed report included 725 adults with obesity or overweight and at least one related complication, but without diabetes.
Those are the treatment-regimen results, which incorporate treatment discontinuation, prohibited obesity medicines, and prolonged dose escalation. The 16.6% result reported elsewhere is an efficacy-estimand result. It estimates a different treatment scenario and should not replace the primary 13.0% result.
Survodutide remains investigational. Positive phase 3 results do not mean the drug is FDA-approved or available by prescription.
What survodutide is
Survodutide is a once-weekly injection that activates glucagon and GLP-1 receptors. Ozempic (semaglutide) and Wegovy (semaglutide) activate GLP-1 receptors, while Mounjaro (tirzepatide) and Zepbound (tirzepatide) activate GIP and GLP-1 receptors.
Researchers are studying whether adding glucagon-receptor activity affects body weight, liver fat, and other metabolic measures. That mechanism does not establish superiority to an approved medicine. SYNCHRONIZE-1 compared survodutide with placebo, not semaglutide or tirzepatide.
SYNCHRONIZE-1 phase 3 results
Participants were assigned to survodutide 3.6 mg, survodutide 6.0 mg, or placebo, alongside lifestyle counseling. At week 76, the prespecified treatment-regimen analysis found:
| Assigned group | Average body-weight change | Participants losing at least 5% |
|---|---|---|
| Survodutide 3.6 mg | -12.2% | 72.6% |
| Survodutide 6.0 mg | -13.0% | 71.9% |
| Placebo | -5.4% | 46.3% |
The experimental doses are trial assignments, not prescribing instructions. Individual results varied.
Why 16.6% also appears in coverage
Boehringer Ingelheim previously reported up to 16.6% average weight loss under an efficacy estimand. That analysis estimates the effect under assumptions tied to remaining on treatment. The peer-reviewed paper made the treatment-regimen estimand the primary analysis. Both can be reported, but the estimand must stay attached to the number.
Earlier phase 2 results
The phase 2 obesity trial enrolled adults with a BMI of at least 27 and without diabetes. At 46 weeks, its planned-treatment analysis reported average reductions of 6.2% with 0.6 mg, 12.5% with 2.4 mg, 13.2% with 3.6 mg, and 14.9% with 4.8 mg, compared with 2.8% for placebo.
Only about 60% of treated participants completed the 46-week treatment period. That makes the analysis method and assumptions about missing data important.
GLP-1 medication news, in plain English
New approvals, pens, pills, prices and label changes across GLP-1 medications. One free email a week.
Separate liver findings
The phase 3 SYNCHRONIZE-MASLD report studied 218 randomized adults with obesity or overweight and at-risk metabolic dysfunction-associated steatotic liver disease (MASLD). At 48 weeks:
| Outcome | Efficacy estimand | Treatment-regimen estimand |
|---|---|---|
| At least 30% relative liver-fat reduction by MRI | 84.2% vs 24.3% placebo | 68.5% vs 28.6% placebo |
| Average body-weight change | -12.2% vs -1.0% placebo | -8.7% vs -1.4% placebo |
The liver endpoint measured the proportion reaching an MRI threshold. It does not prove biopsy-confirmed MASH resolution, fibrosis reversal, or fewer cases of liver failure.
Boehringer also reported liver-fat and visceral-fat findings from an MRI substudy within SYNCHRONIZE-1. Those results come from a different population and analysis and should not be merged with SYNCHRONIZE-MASLD.
Side effects and study limits
In SYNCHRONIZE-1, gastrointestinal symptoms occurred in 80.9% of participants assigned to 3.6 mg, 89.7% assigned to 6.0 mg, and 47.9% assigned to placebo. Gastrointestinal adverse events led to treatment discontinuation in 17.8%, 20.2%, and 2.9%, respectively. The peer-reviewed NEJM report described most gastrointestinal events as mild or moderate. No deaths were reported during the trial.
The study excluded people with diabetes and ran for 76 weeks. It cannot settle longer-term safety or show how survodutide compares directly with approved obesity medicines.
FDA and access status
Survodutide is not FDA-approved. Development designations such as Fast Track or Breakthrough Therapy can speed parts of the review process, but they do not authorize sale. No reliable source establishes an approval date, retail price, insurance policy, or approved dose schedule.
The registered studies include SYNCHRONIZE-1 and SYNCHRONIZE-MASLD. A registry listing does not mean a study is open or that a person qualifies.
Do not use products labeled "research use only" as treatment. People seeking care now can discuss approved options with a licensed clinician.
This article summarizes research and is not medical advice. Experimental trial doses are not prescribing instructions.
Frequently asked questions
What is survodutide?
Survodutide, also called BI 456906, is an investigational glucagon and GLP-1 receptor dual agonist developed by Boehringer Ingelheim under license from Zealand Pharma. It is not FDA-approved.
How much weight did people lose in the phase 3 trial?
In the prespecified primary treatment-regimen analysis of SYNCHRONIZE-1, average weight loss at 76 weeks was 12.2% with 3.6 mg and 13.0% with 6.0 mg, versus 5.4% with placebo. The separate 16.6% figure came from the efficacy estimand.
Is survodutide FDA-approved?
No. Survodutide remains investigational, and no approved launch date, price, or prescribing schedule has been established.
